The Latin America, Middle East and Africa Liver Disease Diagnostics Market is expected to witness market growth of 7.6% CAGR during the forecast period (2020-2026).
Increasing the prevalence of the liver disease has made it important to increase awareness. Government and non-profit organizations play a vital role in a growing understanding of liver disease around the world. These organizations promote awareness of liver-related diseases and support research and development in the prevention, treatment, and cure of liver disease.
In underdeveloped countries, however, the presence of an unmet clinical need for liver disease is likely to fuel the demand for diagnosis and treatment of liver disease. In addition to that, the rise to people's disposable income is projected to further expand the demand because they become more inclined to invest freely in advanced treatment. Furthermore, the growing acceptance of unhealthy lifestyles is described as a core factor of growth for liver disease diagnostics and treatment.
Liver disease in the United Kingdom has increased dramatically, particularly in people under 65 years of age - a marked contrast to all other major causes of death that have decreased in younger age groups. The epidemic was caused by alcohol, obesity and hepatitis C. LFTs are usually abnormal due to a number of causes, such as drinking too much, fatty liver due to obesity, infections, rare liver diseases, and certain cancers - but they may be a symptom of potentially fatal liver disease.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.
Scope of the Study
Market Segmentation:
By End User
By Diagnosis Technique
By Country
Companies Profiled
Unique Offerings from the Publisher
Increasing the prevalence of the liver disease has made it important to increase awareness. Government and non-profit organizations play a vital role in a growing understanding of liver disease around the world. These organizations promote awareness of liver-related diseases and support research and development in the prevention, treatment, and cure of liver disease.
In underdeveloped countries, however, the presence of an unmet clinical need for liver disease is likely to fuel the demand for diagnosis and treatment of liver disease. In addition to that, the rise to people's disposable income is projected to further expand the demand because they become more inclined to invest freely in advanced treatment. Furthermore, the growing acceptance of unhealthy lifestyles is described as a core factor of growth for liver disease diagnostics and treatment.
Liver disease in the United Kingdom has increased dramatically, particularly in people under 65 years of age - a marked contrast to all other major causes of death that have decreased in younger age groups. The epidemic was caused by alcohol, obesity and hepatitis C. LFTs are usually abnormal due to a number of causes, such as drinking too much, fatty liver due to obesity, infections, rare liver diseases, and certain cancers - but they may be a symptom of potentially fatal liver disease.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited.
Scope of the Study
Market Segmentation:
By End User
- Hospitals, Laboratories and Other End Users
By Diagnosis Technique
- Imaging
- Biopsy
- Endoscopy
- Laboratory tests and
- Other Diagnosis Techniques
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Boston Scientific Corporation
- Siemens AG (Siemens Healthineers)
- Bayer AG
- Merck & Co., Inc.
- Sanofi S.A.
- Novartis AG
- Pfizer, Inc.
- Randox laboratories limited
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Liver Disease Diagnostics Market by End User
Chapter 4. LAMEA Liver Disease Diagnostics Market by Diagnosis Technique
Chapter 5. LAMEA Liver Disease Diagnostics Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Boston Scientific Corporation
- Siemens AG (Siemens Healthineers)
- Bayer AG
- Merck & Co., Inc.
- Sanofi S.A.
- Novartis AG
- Pfizer, Inc.
- Randox laboratories limited
Methodology
LOADING...
